seekingalpha.com
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Viatris Inc.VTRSNASDAQ
Loading
Latest News
Loading news...
gurufocus.com
Viatris Inc (VTRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives
Total Revenue (Q4 2025): $3.7 billion, up 1% versus prior year, excluding Indore impact.Total Revenue (Full Year 2025): $14.3 billion, up 2% versus prior year,
zacks.com
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
VTRS beats Q4 estimates on 5% revenue growth, boosted by strong Brands sales and Greater China gains, while returning over $1B to shareholders in 2025.
zacks.com
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates
Viatris (VTRS) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.54 per share a year ago.
zacks.com
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
reuters.com
Viatris forecasts 2026 profit below estimates on India manufacturing woes
Drugmaker Viatris forecast annual profit below analysts' expectations on Thursday, after a fire at one of its major plants in India disrupted operations.
prnewswire.com
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
Reports Fourth-Quarter Total Revenues of $ 3.7B and Full-Year 2025 Total Revenues of $ 14.3B Meets or Exceeds 2025 Financial Guidance Across All Key Metrics[1] Returns More Than $1B to Shareholders in 2025; Expects Balanced Capital Allocation Approach for 2026 Provides 2026 Financial Guidance; Positioned for Sustainable Growth Anticipates Regulatory Decisions for Six Product Candidates in 2026 and Multiple Important Pipeline Milestones Completes Enterprise-Wide Strategic Review; Expects to Deliver $650M in Total Cost Savings With Reinvestment of up to $250M Over the Next 3 Years PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced robust financial results for the fourth quarter and full year 2025. The Company also announced it has completed its enterprise-wide strategic review and expects to deliver meaningful net cost savings while enabling reinvestment in areas that enhance the growth profile and long-term competitiveness of the Company.
prnewswire.com
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2026, to shareholders of record as of the close of business on March 9, 2026.
prnewswire.com
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
FDA PDUFA Goal Date Set for October 17, 2026 PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia. The FDA has assigned a PDUFA goal date of October 17, 2026.
zacks.com
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Viatris (VTRS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
zacks.com
What's in Store for These 5 Medical Companies This Earnings Season?
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
seekingalpha.com
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
Upcoming launches between 2026–2027, including fast-acting meloxicam, cenerimod, and selatogrel, could support a return to mid-single-digit sales growth and improve margins. With FCF yield above 10% and solid deleveraging capacity, Viatris combines deep-value characteristics with optionality from targeted acquisitions and shareholder returns. VTRS also anticipates $500 million in net cost savings by 2028, with reinvestment supporting higher-value brands.
zacks.com
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com
Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026
NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 3, 2026 at 11:00 AM ET.
seekingalpha.com
Dividend Income: Lanny's December 2025 Summary
In December, we received a dividend income total of $8,010.54. The retirement accounts are composed of HSA investments, ROTH and traditional IRAs, as well as our work 401(k) accounts. In total, dividend increases created $4.44 in additional passive dividend income.
prnewswire.com
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m.
prnewswire.com
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026.
prnewswire.com
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to commercialize the treatment. Future launches are planned in multiple countries over the next several years, supporting Viatris' strategy to expand access to the treatment in key markets outside of the U.S. and Europe.
seekingalpha.com
Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
gurufocus.com
Burney U.S. Factor Rotation ETF Buys Shares of Viatris Inc (NAS:VTRS)
Summary Burney U.S. Factor Rotation ETF initiated a new position in Viatris Inc by purchasing 222,793 shares, bringing its total holdings to 222,793 shares a